# Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1

> **NCT02620280** · PHASE3 · COMPLETED · sponsor: **Fondazione Michelangelo** · enrollment: 278 (actual)

## Conditions studied

- Invasive Ductal Breast Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Abraxane
- **DRUG:** MPDL3280A
- **PROCEDURE:** Surgery
- **DRUG:** Anthra

## Key facts

- **NCT ID:** NCT02620280
- **Lead sponsor:** Fondazione Michelangelo
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2024-01
- **Final completion:** 2024-01-07
- **Target enrollment:** 278 (ACTUAL)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02620280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02620280, "Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02620280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*